Skip to main content
. 2024 Feb 28;13(2):321–333. doi: 10.21037/tlcr-23-804

Figure 1.

Figure 1

Flow diagram of the cohort selection. a, one patient was additionally excluded due to limited tissue availability for the c-MET and EGFR analysis; b, patients who received crizotinib without further generations of ALK inhibitors during the follow-up; c, patients who received second- or third-generation ALK inhibitors as any line of therapy during the follow-up. NSCLC, non-small cell cancer; ALK, anaplastic lymphoma kinase.